iTeos Therapeutics, Inc. ITOS
Set alert
10.15 0.00 0.00%
At close · Aug 29
10.15 Day range 10.15
52-week range unavailable
- YTD
- +32.16%
- 1 year
- -40.82%
- Open
- 10.15
- Prev close
- 10.15
- Mkt cap
- 268.52M
- Vol
- 11.01M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.15
- High
- 10.15
- Forward P/E
- -1.26
- Beta
- 1.39
- Short ratio
- 3.66
- Inst. own
- 103.92%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 8.57
- 200-d avg
- 12.79
- 1y target
- 25.00
5Y chart
Events in this range
- Mar 6, 2024Earnings: —; estimate -1.03; surprise —%
- May 10, 2024Earnings: -1.07; estimate -1.02; surprise -4.9%
- May 10, 2024Earnings: —; estimate -1.02; surprise —%
- Aug 8, 2024Earnings: -0.18; estimate -1.04; surprise 82.69%
- Aug 8, 2024Earnings: —; estimate -1.04; surprise —%
- Aug 12, 2024Rating: JP Morgan · Overweight → Overweight
- Aug 13, 2024Rating: Wells Fargo · — → Overweight
- Sep 16, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 12, 2024Earnings: -1.05; estimate -1.18; surprise 11.02%
- Nov 15, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 13, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 19, 2024Rating: Wells Fargo · Overweight → Overweight
Signals (56)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Aug 25, 2025 | 1 year ago |
| SMA: Bullish | May 16, 2025 | 1 year ago |
| SMA: Bullish | May 16, 2025 | 1 year ago |
| SMA: Bearish | May 9, 2025 | 1 year ago |
| SMA: Bearish | May 9, 2025 | 1 year ago |
| SMA: Bullish | May 2, 2025 | 1 year ago |
| SMA: Bullish | Apr 25, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 17, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 10, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 30, 2025 | 1 year ago |
| SMA: Bearish | Sep 16, 2024 | 2 years ago |
| SMA: Bearish | Sep 9, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 9, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 26, 2024 | 2 years ago |
| SMA: Bullish | Aug 19, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 12, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| SMA: Bullish | Jul 15, 2024 | 2 years ago |
| SMA: Bearish | Jun 24, 2024 | 2 years ago |
| RSI: Overbought | May 10, 2024 | 2 years ago |
| SMA: Bullish | May 3, 2024 | 2 years ago |
| SMA: Bullish | Apr 26, 2024 | 2 years ago |
| SMA: Bearish | Apr 19, 2024 | 2 years ago |
| SMA: Bearish | Apr 19, 2024 | 2 years ago |
| SMA: Bullish | Mar 7, 2024 | 2 years ago |
| SMA: Bullish | Feb 29, 2024 | 2 years ago |
| SMA: Bearish | Feb 15, 2024 | 2 years ago |
| SMA: Bullish | Feb 8, 2024 | 2 years ago |
| SMA: Bearish | Jan 25, 2024 | 2 years ago |
| SMA: Bullish | Dec 7, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 7, 2023 | 2 years ago |
| RSI: Oversold | Oct 10, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 3, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 5, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 22, 2023 | 3 years ago |
| SMA: Bearish | Jun 20, 2023 | 3 years ago |
| MACD: Buy Signal | May 23, 2023 | 3 years ago |
| SMA: Bullish | May 16, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 14, 2023 | 3 years ago |
| SMA: Bearish | Feb 14, 2023 | 3 years ago |
| SMA: Bearish | Feb 14, 2023 | 3 years ago |
| SMA: Bullish | Jan 24, 2023 | 3 years ago |
| SMA: Bullish | Jan 17, 2023 | 3 years ago |
| SMA: Bearish | Dec 20, 2022 | 3 years ago |
| SMA: Bearish | Dec 20, 2022 | 3 years ago |
| SMA: Bullish | Dec 13, 2022 | 3 years ago |
| SMA: Bullish | Dec 13, 2022 | 3 years ago |
| SMA: Bearish | Dec 6, 2022 | 3 years ago |
| SMA: Bullish | Nov 15, 2022 | 3 years ago |
| MACD: Buy Signal | Oct 17, 2022 | 4 years ago |
| MACD: Sell Signal | Oct 10, 2022 | 4 years ago |
| SMA: Bearish | Aug 22, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 18, 2022 | 4 years ago |
| SMA: Bullish | Jul 1, 2022 | 4 years ago |
| SMA: Bearish | Jan 24, 2022 | 4 years ago |
Key statistics
- Market cap
- 268.52M
- Enterprise value
- -212.10M
- Trailing P/E
- 0.00
- Forward P/E
- -1.26
- PEG ratio
- 0.00
- Price / sales
- 7.67
- Price / book
- 0.43
- EPS (TTM)
- -3.14
- Beta
- 1.39
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 35.00M
- Revenue growth
- 0.00%
- Free cash flow
- -90.69M
- Total cash
- 488.71M
- Total debt
- 5.53M
- Return on equity
- -19.72%
- Shares outstanding
- 36.53M
- Short % of float
- 10.05%
- 50-day average
- 8.57
- 200-day average
- 12.79
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 25.00 +146.3% upside
Now 10.15
- Target (low)
- 16.00
- Target (mean)
- 25.00
- Target (high)
- 47.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy3
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -1.02.
Financials — quick view
ITOS Revenue — quarterly 0
ITOS Net income — quarterly -78.73M
ITOS EPS — quarterly -1.81
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -1.18 | -1.05 | +0.13 | +11.02% |
| Aug 8, 2024 | Jun 1, 2024 | -1.04 | -0.18 | +0.86 | +82.69% |
| Aug 8, 2024 | Jun 1, 2024 | -1.04 | — | — | — |
| May 10, 2024 | Mar 1, 2024 | -1.02 | -1.07 | -0.05 | -4.90% |
| May 10, 2024 | Mar 1, 2024 | -1.02 | — | — | — |
| Mar 6, 2024 | Dec 1, 2023 | -1.03 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | Wells Fargo | main | Overweight | Overweight |
| Dec 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2024 | Wells Fargo | init | — | Overweight |
| Aug 12, 2024 | JP Morgan | main | Overweight | Overweight |
About iTeos Therapeutics, Inc.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- iteostherapeutics.com
News
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and KLG on Behalf of Shareholders
- ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS
- ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders
- ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc.
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of iTeos Therapeutics, Inc. (NASDAQ: ITOS)
- ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders
- iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
- iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
Your note
Sign in to keep a note on ITOS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOXER CAPITAL L L C | Unknown | Stock Award(Grant) | May 9, 2024 | 0 |
| CALL MATTHEW A MBA | Chief Operating Officer | Stock Award(Grant) | Dec 4, 2023 | 137,898 |
| DETHEUX MICHEL | Chief Executive Officer | Stock Award(Grant) | Dec 4, 2023 | 58,903 |
| FELTQUATE DAVID M.D., PH.D. | Officer | Stock Award(Grant) | Dec 5, 2024 | 47,000 |
| GALL MATTHEW | Chief Financial Officer | Purchase | Nov 18, 2024 | 65,429 |
| MCGRATH YVONNE | Officer | Stock Award(Grant) | Dec 4, 2023 | 31,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.63% | 3,882,549 | 28.54M | Sep 29, 2024 |
| RA Capital Management, L.P. | 8.72% | 3,184,711 | 23.41M | Sep 29, 2024 |
| Boxer Capital, LLC | 8.07% | 2,946,915 | 21.66M | Sep 29, 2024 |
| MPM Asset Management, LLC | 7.50% | 2,738,785 | 20.13M | Sep 29, 2024 |
| Tang Capital Management, LLC | 6.59% | 2,407,800 | 17.70M | Sep 29, 2024 |
| MPM BioImpact Capital LLC | 4.78% | 1,745,943 | 12.83M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.34% | 855,645 | 6.29M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.84% | 671,531 | 4.94M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.57% | 572,858 | 4.21M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.17% | 426,251 | 3.13M | Sep 29, 2024 |
| BlackRock Advantage Small Cap Core Fund | 1.11% | 405,245 | 2.98M | Aug 30, 2024 |
| Fidelity Small Cap Index Fund | 0.72% | 264,212 | 1.94M | Aug 30, 2024 |